Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. lessened its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 36.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,102 shares of the medical research company's stock after selling 3,427 shares during the quarter. Russell Investments Group Ltd.'s holdings in Bio-Rad Laboratories were worth $2,001,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Venturi Wealth Management LLC raised its stake in Bio-Rad Laboratories by 2,175.0% during the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock valued at $30,000 after buying an additional 87 shares in the last quarter. Picton Mahoney Asset Management lifted its stake in Bio-Rad Laboratories by 55.6% during the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after purchasing an additional 35 shares during the last quarter. Asset Planning Inc acquired a new position in Bio-Rad Laboratories in the fourth quarter worth $33,000. UMB Bank n.a. increased its stake in Bio-Rad Laboratories by 41.6% during the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after purchasing an additional 32 shares during the last quarter. Finally, Cape Investment Advisory Inc. bought a new stake in Bio-Rad Laboratories during the fourth quarter valued at $38,000. Institutional investors own 65.24% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on BIO shares. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Wells Fargo & Company lowered their target price on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Finally, StockNews.com downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Monday, February 17th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $380.20.

Bio-Rad Laboratories Stock Performance

Shares of NYSE:BIO traded up $1.04 during trading hours on Thursday, hitting $249.89. The stock had a trading volume of 48,476 shares, compared to its average volume of 314,126. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. The stock's fifty day simple moving average is $252.39 and its 200 day simple moving average is $309.79. The firm has a market capitalization of $7.00 billion, a price-to-earnings ratio of -3.84 and a beta of 1.12. Bio-Rad Laboratories, Inc. has a 1-year low of $215.38 and a 1-year high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. Sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.